Conner Feldman

Dec 4, 2024 | advancingrna.com | Tyler Menichiello |Conner Feldman |Millipore Sigma |Optimizing mRNA

Leading experts in gene therapy discuss CMC strategy for platform technologies, product lifecycle management, and the role CDMOs play in moving the space forward. This segment features a discussion around the obstacles to establishing a standardized production pipeline for mRNA therapeutics across the industry as well as some the approaches being considered to standardize cold chain management protocols for mRNA products.

Jun 11, 2024 | outsourcedpharma.com | Millipore Sigma |Conner Feldman |Louis Garguilo

By Conner Feldman, MilliporeSigma The COVID-19 pandemic has spurred a surge in investment and research directed at mRNA therapeutics. These drugs hold promise for the rapid development of vaccines, gene therapies, and personalized medicine, but challenges related to stability, delivery, and manufacturing remain. A key advantage of mRNA is its speedy development, making it ideal for tackling emerging infectious diseases.